An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de Hierro phase I/II clinical trial  by Vaquero, Jesús et al.
CLINICALTRIALS
An approach to personalized cell therapy in chronic complete
paraplegia:The Puerta de Hierro phase I/II clinical trial
JESÚS VAQUERO1,2, MERCEDES ZURITA2, MIGUEL A. RICO2, CELIA BONILLA2,
CONCEPCION AGUAYO2, JESÚS MONTILLA3, SALVADOR BUSTAMANTE4,
JOAQUIN CARBALLIDO4, ESPERANZA MARIN5, FRANCISCO MARTINEZ5,
AVELINO PARAJON1, CECILIA FERNANDEZ1 & LAURA DE REINA1 FOR THE
NEUROLOGICAL CELL THERAPY GROUP†
1Neurosurgery Service, Department of Surgery,Hospital Puerta de Hierro-Majadahonda and Autonomous University,
Madrid, Spain, 2Neurological Cell Therapy Unit, Hospital Puerta de Hierro-Majadahonda and Autonomous
University,Madrid, Spain, 3Rehabilitation Service, Hospital Puerta de Hierro-Majadahonda and Autonomous
University,Madrid, Spain, 4Urology Service, Hospital Puerta de Hierro-Majadahonda and Autonomous University,
Madrid, Spain, and 5Clinical Neurophysiology Service, Hospital Puerta de Hierro-Majadahonda and Autonomous
University,Madrid, Spain
Abstract
Background aims. Cell transplantation in patients suffering spinal cord injury (SCI) is in its initial stages, but currently there
is confusion about the results because of the disparity in the techniques used, the route of administration, and the criteria for
selecting patients. Methods. We conducted a clinical trial involving 12 patients with complete and chronic paraplegia (average
time of chronicity, 13.86 years; SD, 9.36). The characteristics of SCI in magnetic resonance imaging (MRI) were evaluated
for a personalized local administration of expanded autologous bone marrow mesenchymal stromal cells (MSCs) supported
in autologous plasma, with the number of MSCs ranging from 100 × 106 to 230 × 106. An additional 30 × 106 MSCs were
administered 3 months later by lumbar puncture into the subarachnoid space. Outcomes were evaluated at 3, 6, 9 and 12
months after surgery through clinical, urodynamic, neurophysiological and neuroimaging studies. Results. Cell transplanta-
tion is a safe procedure. All patients experienced improvement, primarily in sensitivity and sphincter control. Infralesional motor
activity, according to clinical and neurophysiological studies, was obtained by more than 50% of the patients. Decreases in
spasms and spasticity, and improved sexual function were also common findings. Clinical improvement seems to be dose-dependent
but was not influenced by the chronicity of the SCI. Conclusion. Personalized cell therapy with MSCs is safe and leads to
clear improvements in clinical aspects and quality of life for patients with complete and chronically established paraplegia.
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“In scientific research, topics are not depleted.What
usually happens is that there are men exhausted on
the topics”
Santiago Ramón y Cajal, 1897.
Introduction
Spinal cord injury (SCI) is one of the most devastat-
ing diseases and often causes permanent disability in
young patients. In seeking a cure, these patients often
undergo treatments that lack scientific and method-
ological rigor.
At present, cell therapy is a therapeutic promise
in this field of research [1–9] but still subject to many
uncertainties, with significant confusion due to the dis-
parity of protocols, selection of subjects, cell type, dose
and routes of administration used.
In experimental studies, it is noteworthy that the
functional recovery of paraplegic animals after mesen-
chymal stromal cell (MSC) transplantation starts before
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tissue regeneration occurs to allow the passage of as-
cending and descending axons.Therefore, it is obvious
that after MSC transplantation into injured central
nervous system (CNS) must exist various repair pro-
cesses, including the release of neurotrophic factors by
the transplanted stem cells, or the activation of endog-
enous mechanisms of the spinal cord, able to partially
restore neurological functions previously abolished
[10–18].
Considering previous experimental studies suggest-
ing the advisability of transplanting enough cells, our
efforts must be aimed at achieving the highest possi-
ble survival of MSCs, once transplanted, and suggest
that administration of repeated doses of cell therapy
could be beneficial. In this regard, various experimen-
tal studies showed that MSCs can reach areas of SCI
after being deposited in the subarachnoid space [19–23],
an observation that must be taken into account when
applying these techniques in patients. Moreover, our
preclinical experience with adult paraplegic pigs shows
that local cell therapy for SCI requires attention to nu-
merous technical details, such as the morphology of the
lesion, an adequate cell suspension medium, caliber of
the injection needle, rate of cell administration in the
injured tissue, and achieving a high concentration of
cells in the smallest possible volume, in order not to
produce added damage to the spinal cord [13,24].
On the other hand, the prospect of achieving
human cell therapy medicaments using allogeneic cells
to the treatment of SCI obviously is a legitimate ob-
jective by pharmaceutical companies, but we believe
any kind of cell therapy requiring immunosuppres-
sion is unacceptable due to repeated urinary infections
that often plague these patients.
These considerations lead us to develop the present
clinical trial, aimed at evaluating the safety and effi-
cacy of personalized cell therapy with autologous MSCs
obtained from bone marrow, in patients with com-
plete and chronic paraplegia.
Methods
Study design
The present clinical trial (ClinicalTrials.gov identifier:
NCT01909154; EudraCT identifier: 2010-023285-46)
included 12 patients (male/female: 9/3) suffering chronic
complete paraplegia (ASIA A) due to traumatic SCI
in the dorsal (thoracic) region. Mean age was 40.5 years
(SD, 8.75 years), and time from SCI to treatment ranged
from 3.17 to 26.75 years (mean, 13.86 years; SD, 9.36
years). Clinical and demographic data and the flow chart
of the patients can be seen in Supplementary Table S1
and Supplementary Figure S1.
The trial protocol was approved by the ethics com-
mittee of Puerta de Hierro-Majadahonda Hospital and
by the Spanish Agency for Medicaments and Health
Products (AEMPS), and was conducted in accor-
dance with the principles of the Declaration of Helsinki
[25] and good clinical practice guidelines [26]. Adverse
events were collected throughout the follow-up and
classified according to the Medical Dictionary for Reg-
ulatory Activities (MedDRA v. 18.1).
Clinical scores were obtained from each patient, prior
to cell therapy and at 3, 6, 9 and 12 months after treat-
ment by means of the following scales: the scale provided
by the American Spinal Injury Association (ASIA) [27],
the SCI functional rating scale of the International As-
sociation of Neurorestoratology (IANR-SCIFRS scale)
[28], the Functional Independence Measure (FIM) scale
[29] and the Barthel scale [30] for the study of func-
tional independence in the activities of daily life (ADL),
the Visual Analog Scale (VAS) [31] for the evaluation
of neuropathic pain, the Penn [32] and the modified
Ashworth [33] scales for the evaluation of spasms and
spasticity, respectively, the Geffner scale [34] for the
study of bladder function, and the Neurogenic Bowel
Dysfunction (NBD) scale [35] for the evaluation of
symptoms related to neurogenic bowel dysfunction.
Neurophysiological, urodynamic and magnetic reso-
nance imaging (MRI) studies were also performed
before and after treatment. Additional details are pro-
vided in the Supplementary Appendix, available online
at doi:10.1016/j.jcyt.2016.05.003.
Cell therapy medicament
We used a cell therapy medicament (NC1) based on
our preclinical experience and currently approved as
a medicament under clinical investigation by the
AEMPS (PEI No. 12–141). It consists of autologous
MSCs and autologous plasma as its excipient. Prior to
NC1 preparation, a sample of peripheral blood was re-
trieved from each patient for genomic studies to rule
out chromosomal abnormalities that could discour-
age cell expansion and to obtain a genetic fingerprint
(KaryoNIM Stem Cells and KaryoNIM STR test, re-
spectively; NIMGenetics; additional information is
provided in the Supplementary Appendix). For ob-
taining the excipient, as a first step in the preparation
of the NC1, we start with the removal of 500 cc of pe-
ripheral blood from each patient. In our cleanroom,
blood was centrifuged at 900g for 8 min to obtain the
plasma fraction, which is aliquoted in 15 mL tubes and
stored at -80°C until the medicament formulation.
Culture of MSCs
Approximately 2 weeks later, 50 mL of bone marrow
was aspirated under aseptic conditions from the iliac
bones of each patient, immediately anticoagulated by
a 5 mL solution composed of 100 IU/mL sodium
heparin Chiesi (Chiesi España) and 104 IU/104 μg
penicillin-streptomycin (BioWhittaker-Lonza) and sent
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to our cleanroom for culture and expansion under good
manufacturing practice (GMP). Mononuclear cells
(MNC) were separated by density gradient using an
automated cell-processing system (SEPAX, BioSafe).
Then, they were plated at a density of 16 × 104 to
20 × 104 cells/cm2, in 175 cm2 flasks on Alpha-
Minimum Essential Medium (MEM) with Earle’s
Balanced Salt Solution (BSS), and supplemented with
20% Australian prion-free fetal bovine serum (FBS)
(Lonza; Lot Number, 9SB006), 200 mmol/L
L-glutamine (BioWhittaker-Lonza) and 104 IU/
104 μg penicillin-streptomycin (BioWhittaker-Lonza).
The cultures were maintained at 37°C in a hu-
midified 5% CO2 atmosphere for 3 days, after which
nonadherent cells were removed by replacing the
medium. When the cultures approached confluence
(90–100%), adherent cells were detached by treat-
ment with trypsin/ethylenediamine tetraacetic acid
(EDTA) solution (BioWhittaker-Lonza). Neutraliza-
tion of trypsin and subsequent washing was performed
with Alpha-MEM medium supplemented with 10%
FBS and 2 mmol/L L-glutamine, centrifuging at
1250 rpm for 10 min. After study of viability, cells were
cultured to obtain the required number according to
the plan previously made for each patient. Cells were
replated at a density of 3000–5000 cells/cm2 in factory
farming of 4 floors with free-antibiotic Alpha-MEM
medium supplemented with 10% FBS and 2 mmol/L
L-glutamine, and the culture was maintained renew-
ing the medium every 3–4 days until a confluence of
90–100%. Once the culture reached confluency, it was
prepared to obtain the bulk of MSCs. At this time,
MSCs were detached with trypsin/EDTA and washed
with Hank’s BSS medium (BioWhittaker-Lonza)
supplemented with 5% albumin (20% albumin,
Grifols). After that, MSCs were resuspended with the
previously obtained autologous plasma to remove traces
of the washing medium. After cell counting, MSCs
for the second dose were separated and then
cryopreserved, at a concentration of 2.2 × 106 cells/
mL in a FBS solution, in dimethylsulphoxide (DMSO;
Miltenyi Biotec). For this, we used a liquid nitrogen-
free controlled rate freezer (EF 600, Grant-Asymptote).
Finally, the MSCs for surgical administration were for-
mulated, according to the number scheduled for each
patient, after a new centrifugation at 1250 rpm for
10 min.
To prepare the second dose, cryopreserved MSCs
were thawed in a thermostatic bath at 37°C, washed
with antibiotic-free Alpha-MEM medium supple-
mented with 10% FBS and 2 mmol/L L-glutamine,
and centrifuged at 1250 rpm for 10 min. After this,
a cell count was performed and MSCs were plated
at a concentration of 10000–15000 MSCs/cm2 in
175 cm2 culture flasks with antibiotic-free Alpha-
MEM medium supplemented with 10% FBS and
2 mmol/L L-glutamine to reach a confluence of
90–100% over a period of 4–5 days, and then we pro-
ceeded in the same way as with the first MSCs dose.
Formulation and packaging
After obtaining the MSCs for surgical or second dose
administration, they were resuspended in the autolo-
gous plasma at a cell concentration of 100,000 cells/μL.
After formulation, the cell therapy medicament
was packaged in sterile and endotoxins-free 1-mL
Hamilton microsyringes, with a 20-guage needle. Sub-
sequently the needle was removed and a sterile luer
plug nut was placed on the end of each preloaded
syringe. Microsyringes with the medicament were
placed inside a sterile metal box, which was also double
bagged before being transported to the operating room
for cell transplantation.
Phenotypic characterization of MSCs
For phenotypic characterization of MSCs, monoclo-
nal antibodies conjugated with different fluorochromes
(Fluorescein [FITC]/Phycoerythrin [PE]/Alexa-647
[AL-647]), which combine a number of both posi-
tive and negative MSCs membrane markers, were used.
Positive markers used were CD105 FITC (R&D
Systems); CD90 AL-647 (AbD Serotec, OX5 1GE);
HLA Class I FITC (Cytognos); CD73 PE (BD Bio-
science) and CD166 PE (R&D Systems). Negative
markers used were CD34 PE (BD Bioscience);
HLA class II PE (Cytognos); CD80 AL-647 (AbD
Serotec); CD45 FITC (Cytognos); and CD31 FITC
(Cytognos). Furthermore, suitable isotopic controls
for FITC, PE (Cytognos) and AL-647 (AbD Serotec),
respectively, were used as controls for specificity of the
monoclonal antibodies. The labeled cells were ac-
quired with a flow cytometer FC500 MPL Cytomics
(Beckman Coulter) using the MXP software (Beckman
Coulter). Nonviable cells were discarded using the la-
beling reagent LIVE&DEAD (Invitrogen), and the
collected data were analyzed with the CXP analysis
software, version 2.1 (Beckman Coulter). Criteria for
the administration of MSCs in our present clinical
trial included a viability >95%, absence of microbial
contamination (bacteria, fungus, virus or myco-
plasma), expression of CD105, CD90, HLA I, CD73
and CD166 for >90% of cells and absence of
CD34, CD80, HLA II, CD45 and CD31 (expres-
sion of each < 5%), as assessed by flow cytometry
(Supplementary Figure S2).
Surgical planning
In all patients, basal neuroimaging studies were used
to make a surgical plan for each patient so that a greater
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number of cells could be administered into the sus-
pected cystic areas and fewer cells could be
administered into the areas of normal appearance, to
prevent additional damage to the spinal cord. As a
result of this planning, the number of injections of the
cell therapy medicament in areas of SCI ranged from
3–7 (average, 4 microinjections/patient), and the volume
of medicament in each microinjection ranged from 50–
1500 μl (average, 360 μL/microinjection). Given that
our cell therapy medicament had a concentration of
105 cells/μL, the amount of administered cells per mi-
croinjection ranged from 5 × 106 MSCs to 150 × 106
MSCs (average, approximately 36 × 106 MSCs). In
each patient, in addition to injections into the injured
spinal cord tissue, 30 × 106 MSCs (300 μL) were ad-
ministered in the perilesional subarachnoid space by
means of an intrathecal catheter (mod BOC 8711,
Medtronic Inc.). Intramedullary injections of MSCs
were performed through a laminectomy and durotomy,
and we used a microinjection pump (mod 310,
Stoelting Co.) connected to a 100-μL Hamilton syringe
with a 20-gauge needle, at a microinjection rate of
10 μL/min, which was modified depending on the mor-
phological characteristics of the lesion and the tissue
consistency. After cell administration, the dura mater
was hermetically closed, to prevent leakage. Three
months after surgery, all patients received another
30 × 106 MSCs into the subarachnoid space by lumbar
tapping through a 20-gauge needle.The total number
of MSCs administered to each patient ranged from
130 × 106 to 260 × 106 (mean, 202.5 × 106; SD,
46.73 × 106). Surgical planning in the patients of the
series is provided in the Supplementary Appendix (See
Supplementary Figures S3 to S14).
Statistical analysis
Wilcoxon rank test was used to assess the differ-
ences between scores in clinical scales and urodynamic
parameters at different time points. Hypothesis testing
between categorical variables were obtained through
Cochran Q test. Effect sizes (ES) were computed using
the G*Power software (v. 3.1.9.2, Statistical Power
Analysis Software). Correlations were obtained using
Spearman rank correlation coefficient. Differences were
considered significant when P < 0.05. SPSS (v. 21.0,
IBM) and Prism software (v. 5.04, GraphPad Soft-
ware) were used.
Results
In our present clinical trial, the cell expansion process
did not involve any alteration in the genome of the
cells in any of the cases, according to the results ob-
tained after analysis by Array-CGH platform.
Adverse events
During the study, 69 adverse events (AEs) were col-
lected, but only 22 of them (31.8%) were related to
the surgical procedure or cell therapy administra-
tion, and they were considered to be of minor (79.1%)
or moderate (20.9%) intensity. Generally, they con-
sisted of postoperative pain, transient hyperthermia or
subcutaneous collection in the area of the surgical
wound. Most AEs collected during the study were
urinary tract infections (78.57%) in patients with
recurrent urinary infections. Details of collected
AEs are provided in the Supplementary Appendix
(Supplementary Tables S2–S4).
ASIA scale
A significant recovery of sensitivity to pin prick (PPS)
and light touch sensitivity (LTS) has been found after
cell therapy (Table I). Figure 1 shows the derma-
tomes in which our patients recovered sensitivity,
regardless of type or intensity, at 12 months after
surgery.
Prior to cell therapy our patients had absence of
motion in the lower limbs, except for one patient who
had a SCI at D11–D12 and a motor score (MS) of
52. The evolution of MS in the series showed a sig-
nificant difference comparing baseline and 12 months
of follow-up (ES, 0.64; P = 0.026). At that time, six
patients showed recovery in the hip flexor muscles.Two
patients showed recovery in the hip flexor and knee
extensor muscles, and one patient showed improve-
ment in the hip flexor, knee extensor, ankle dorsiflexor,
long toe extensor and ankle plantar flexor muscles, but
only reached active movement against gravity in the
hip flexor muscles.
In Total ASIA (TA) scores, a progressive improve-
ment was observed, without correlation with patient
age, level of SCI or chronicity of paraplegia. However,
there was a high correlation between TA improve-
ment and number of cells administered (at 3 months
P = 0.002, r = 0.807; at 6 months P = 0.005, r = 0.749;
and at 9 months P = 0.013, r = : 0.691; Figure 2). Fur-
thermore, throughout the follow-up, 3 patients moved
from ASIA A to ASIA B, and 1 patient moved from
ASIA A to ASIA C, so, therefore, more than 30% of
patients in the study improved from a complete lesion
to an incomplete lesion (P = 0.029, Supplementary
Table S6). Additional details of the evolution in ASIA
scores are provided in the Supplementary Appendix
(See Supplementary Figures S15–S28).
IANR-SCIFRS scale
The IANR-SCIFRS scale evaluates spinal cord func-
tion through nine sections, with a final section that
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only applies to men and assesses sexual function
(Supplementary Table S7).
In our patients, the mean global IANR-SCIFRS
scale score before treatment was 29.92 points (SD,
2.64), and at end of the study was equal to 37.92 points
(P = 0.002; ES, 0.89). Before treatment, all our pa-
tients showed a “medium degree of functional
disability,” whereas at 12 months after surgery, all pa-
tients show a “mild degree disability.” Furthermore,
there was a correlation between the improvement in
overall scores of the IANR-SCIFRS scale and total
number of cells administered (at 12 months P = 0.017,
r = 0.673), which suggests a dose-dependent effect of
the treatment. Similarly, there was a high correlation
between improvement in TA scores and improve-
ment in overall IANR-SCIFRS scores (at 3 months
P = 0.002, r = 0.804; at 6 months P < 0.0001, r = 0.851;
at 9 months P = 0.001, r = 0.845; and at 12 months
P = 0.001, r = 0.821). Table II shows the scores at each
follow-up interval in the sections of the IANR-
SCIFRS scale showing improvement. Additional
information is provided in the Supplementary
Appendix (see Supplementary Table S9 and
Supplementary Figures S30–S47).
FIM and Barthel scales
The FIM scale showed significant improvement at the
6-month follow-up in both overall score and sphinc-
ter control. At the end of the monitoring study, the
difference with the baseline overall score showed an
ES of 0.64 (P = 0.026). In sphincter control, the dif-
ference showed an ES of 0.66 (P = 0.023). In the
Barthel scale, no significant differences were ob-
served. Additional information is provided in the
Supplementary Appendix (See Supplementary
Table S10).
VAS scale
The analysis showed a decrease in neuropathic pain
during the follow-up that reached statistical signifi-
cance at 12 months (effect size, 0.59). Additional details
are provided in the Supplementary Appendix
(Supplementary Figure S48).
Penn and Ashworth scales
In the Penn scale, a significant improvement was ob-
served soon after surgery (ES, 0.71 at 3 months;
P = 0.014), and was maintained at 6 months (ES, 0.75;
P = 0.009), 9 months (ES, 0.75; P = 0.010) and 12
months (ES, 0.74; P = 0.010).The modified Ashworth
scale showed improvement in spasticity with statisti-
cal significance at 3 months (ES, 0.69; P = 0.017), 6
months (ES, 0.85; P = 0.003), 9 months (ES, 0.85;
P = 0.003) and 12 months (ES, 0.85; P = 0.003). Ad-
ditional details are provided in the Supplementary
Appendix (See Supplementary Figures S49 and S50,
and Supplementary Table S11).
Geffner scale
The analysis of this scale confirmed the bladder func-
tion improvement over baseline values, which reached
statistical significance at the end of the study period
(ES, 0.66; P = 0.023). Additional details are provided
Table I. ASIA scores at different time points.
Score subject Time Mean SD P ES
Motor score Before surgery 50.17 0.58 - -
3 months after surgery 50.17 0.58 1 -
6 months after surgery 50.33 0.78 0.317 -
9 months after surgery 50.92 2.07 0.102 -
12 months after surgery 52.75 4.16 0.026* 0.64
Pin prick score Before surgery 57.83 11.17 - -
3 months after surgery 65.67 10.88 0.005** 0.81
6 months after surgery 70.25 13.88 0.003** 0.85
9 months after surgery 75.33 16.36 0.002** 0.88
12 months after surgery 81.00 16.84 0.002** 0.88
Light touch score Before surgery 57.92 9.42 - -
3 months after surgery 65.42 9.83 0.005** 0.81
6 months after surgery 69.25 10.23 0.003** 0.85
9 months after surgery 74.50 10.52 0.002** 0.88
12 months after surgery 79.50 13.92 0.002** 0.88
Total ASIA score Before surgery 165.92 22.83 - -
3 months after surgery 181.25 22.90 0.005** 0.81
6 months after surgery 189.83 27.83 0.003** 0.85
9 months after surgery 200.75 34.40 0.002** 0.88
12 months after surgery 213.25 37.19 0.002** 0.88
Significant P values are in bold.
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Figure 1. Recovery of sensitivity 12 months after surgery in patients in the study. Dermatomes in red indicate some degree of sensitivity.
Those in yellow indicate preserved sensitivity prior to cell therapy. Blanks indicate total anesthesia. Recovery of sensitivity ranged from
2–14 levels (dermatomes) with a mean of 6.8 (SD, 4.0).
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in the Supplementary Appendix (See Supplementary
Table S12 and Supplementary Figure S51).
NBD scale
After surgery, patients noticed peristalsis, and defe-
cation was modified in terms of frequency and time
needed. Improvement was generally immediate and
described as extremely rewarding. According to the
NBD scale, before cell therapy 7 patients had severe
neurogenic bowel dysfunction, 3 patients had mod-
erate dysfunction and 2 patients had mild dysfunction.
At the end of the follow-up, 7 patients had minimal
dysfunction, 1 patient had mild dysfunction and 4 pa-
tients had moderate dysfunction (ES, 0.81; P = 0.005).
See additional details in the Supplementary Appendix
(Supplementary Table S13 and Supplementary Figures
S52 to S56).
Neurophysiological studies
All patients showed neurophysiological improvement
during the follow-up period. Previous to cell therapy,
none of our patients recorded somatosensory evoked
potentials (SSEPs) nor motor-evoked potentials
(MEPs). The neurophysiological study performed 6
months after surgery showed the appearance of SSEPs
in 5 patients (41.67%) and 2 more 12 months after
surgery (58.3%;ES,0.41;P = 0.008).Regarding MEPs,
2 patients showed an appearance 6 months after surgery,
and an additional patient at 12 months (overall, 3 pa-
tients, 25%;P = 0.097). At 6-month follow-up, EMG
studies with concentric needle showed voluntary muscle
contractions below the level of the SCI in three pa-
tients (25%).At 12 months, the EMG showed voluntary
muscle contraction in muscles below the level of
the SCI in 7 patients (58.3%; ES, 0.44; P = 0.005;
Figure 3, Supplementary Table S14, Supplementary
Figures S58 to S62 and Supplementary videos). Fur-
thermore, at 12 months, polyphasic muscle action
potentials in infralesional muscles, suggesting a process
of active muscle reinnervation, were recorded in 10
patients (83.3%; ES, 0.58; P = 0.001). In 7 patients,
this was induced by voluntary muscle contraction,
and, in the other 3, it was induced by reflex or passive
contraction.Additional details are provided in the Sup-
plementary Appendix.
Urodynamic studies
Urodynamic studies showed improvement in 10 pa-
tients (83%) 12 months after surgery. It consisted of
the possibility of voluntary micturition in the flowmetry
test or in the study of pressure/flow in 5 patients
(41.6%), increased bladder capacity at filling in 8 pa-
tients (66.6%), decreased detrusor pressure at bladder
filling in 9 patients (75%) and increased bladder com-
pliance in 10 patients (83.3%).When these data were
compared with baseline studies, the statistical analy-
sis showed significant improvements in detrusor
Figure 2. Spearman correlation study, showing a dose-dependent efficacy in terms of total number of administered cells and improve-
ment in total ASIA scores.
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pressure (ES, 0.62; P = 0.002) and bladder compli-
ance (ES, 0.83; P = 0.005). However, at the end of
the follow-up period, improvement in maximum
cystometric capacity was not statistically significant
(P = 0.185). See additional information in the Sup-
plementary Appendix (Supplementary Tables S15 and
S16, and Supplementary Figures S63–S65).
Neuroimaging studies
In the neuroimaging studies, 5 patients had spinal
fixation devices that caused artefacts, being difficult
to obtain a reliable analysis of lesion volume. However,
they were not an impediment to study the area and
extent of the SCI and plan for the cell number
and volume to be injected into injured tissue. At the
end of the follow-up, images did not suggest a
worsening. In two cases we did not detect signifi-
cant changes in the basal characteristics of the SCI,
but in the remaining cases, we observed a reduction
or disappearance of intramedullary hyperintense lesions,
suggesting the replacement of a cyst or gliotic tissue
with solid tissue, as a result of the cell therapy
(Figure 4). Additional details and images are provided
Table II. Scores in the sections of the IANR-SCIFRS scale showing improvement.
Score subject Time Mean SD P ES
IANR-SCIFRS overall
score
Before surgery 29.92 2.64
3 months after surgery 34.33 1.97 0.003** 0.85
6 months after surgery 36.08 2.39 0.002** 0.89
9 months after surgery 36.75 2.42 0.002** 0.89
12 months after surgery 37.92 2.23 0.002** 0.89
Lower limb movement Before surgery 0.00 0.00
3 months after surgery 0.16 0.57 1.00 —
6 months after surgery 0.33 0.65 0.173 —
9 months after surgery 0.33 0.65 0.173 —
12 months after surgery 0.50 0.67 0.038* 0.59
Trunk movement Before surgery 4.33 0.99
3 months after surgery 5.17 0.84 0.023* 0.66
6 months after surgery 5.50 0.80 0.010** 0.74
9 months after surgery 5.75 0.62 0.007** 0.78
12 months after surgery 5.75 0.62 0.007** 0.78
Sphincter control Before surgery 0.00 0.00
3 months after surgery 1.42 1.44 0.017* 0.69
6 months after surgery 2.00 1.76 0.011* 0.74
9 months after surgery 2.25 1.71 0.007** 0.77
12 months after surgery 2.92 1.44 0.003** 0.85
Bladder control Before surgery 0.00 0.00
3 months after surgery 1.08 1.14 0.011* 0.73
6 months after surgery 1.25 1.14 0.011* 0.73
9 months after surgery 1.25 1.14 0.011* 0.73
12 months after surgery 1.67 0.89 0.003** 0.86
Bowel control Before surgery 0.00 0.00
3 months after surgery 0.33 0.65 0.102 -
6 months after surgery 0.75 0.75 0.014* 0.71
9 months after surgery 1.00 0.85 0.010** 0.75
12 months after surgery 1.25 0.75 0.004** 0.8
Muscular tension Before surgery 1.33 0.99
3 months after surgery 1.92 0.52 0.038* 0.60
6 months after surgery 2.17 0.58 0.008** 0.76
9 months after surgery 2.25 0.62 0.009** 0.75
12 months after surgery 2.33 0.65 0.006** 0.80
Pain Before surgery 2.00 0.95
3 months after surgery 2.25 0.97 0.180 -
6 months after surgery 2.42 0.90 0.059 -
9 months after surgery 2.42 0.90 0.059 -
12 months after surgery 2.58 0.79 0.038* 0.60
Sexual function Before surgery 1.11 0.78
3 months after surgery 1.56 0.73 0.046* 0.58
6 months after surgery 1.67 0.71 0.025* 0.65
9 months after surgery 1.67 0.71 0.025* 0.65
12 months after surgery 1.67 0.71 0.025* 0.65
Significant P values are in bold.
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in the Supplementary Appendix (Supplementary
Figures S66–S70).
Discussion
In this clinical trial, as a result of the experience gained
on animal models [10–14,16,36], we administered a
cell therapy medicament consisting of autologous
MSCs supported by autologous plasma to patients suf-
fering complete and chronically established paraplegia.
The number of cells that we have directly adminis-
tered into the spinal cord tissue during surgery ranged
between 70 × 106 and 200 × 106 (with a local dose
between 100 × 106 and 230 × 106 if we consider that
during surgery another 30 × 106 cells were always ad-
ministered in the perilesional subarachnoid space).This
variability is due to the planning of treatment after the
morphological study of the SCI. Given that we ad-
ministered 100,000 cells/μL, our purpose was the
administration in each intramedullary target of an ac-
ceptable number of cells, but trying to not produce
additional tissue damage by volume.
Our primary outcome was safety, and assuming that
patients with complete traumatic paraplegia may show
some degree of improvement after the SCI [37], we
only included patients with a long time since SCl.
Surprisingly, we found that all our patients, even
those with the longest chronicity, experienced gradual
improvement in clinical parameters without reaching
Figure 3. Patient 08. Complete paraplegia since 1996 (ASIA A).
SCI level: D6–D7. (A) Surgical planning. Microinjections were per-
formed in 7 different targets in the zones of the SCI and its edges.
30 × 106 MSCs were administered in targets 3–7. In target 2, 20 × 106
MSCs were administered. Furthermore, 30 × 106 MSCs were ad-
ministered into the perilesional subarachnoid space (target 1).The
total number of MSCs administered at surgery was 200 × 106. (B–
G) EMG study 1 year after surgery showing voluntary muscle
contraction with polyphasia in infralesional muscles (B, left rectus
abdominus muscle at D12 level; C, left iliopsoas muscle; D, right
quadriceps muscle;E, left medial gastrocnemius muscle;F, left tibi-
alis anterior muscle; G, right bicep femoris muscle).
Figure 4. MR-myelography images in four patients in the study.
(Above) Arrows show hyperintense lesions in the spinal cord (pos-
sible gliosis or cysts) prior to cell therapy. (Below) Arrows show
the disappearance of these hyperintense lesions 12 months after cell
therapy. (A and E, Patient 06; B and F, Patient 08; C and G, Patient
15; D and H, Patient 16). These patients received in the hyperin-
tense zone between 70 and 150 × 106 cells (mean, 108 × 106; SD,
39 × 106) and all, except patient 16, had changed their classifica-
tion to “incomplete” lesion, according to the ASIA scale.
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a plateau at the end of the follow-up period. The re-
covery of infralesional sensitivity and vegetative
functions, such as bladder, bowel or sexual function,
occurred soon after surgery, suggesting a possible effect
through cytokines released by the transplanted cells,
which activate preserved but non-functional circuits,
rather than a mechanism of nerve pathway regener-
ation. Furthermore, MS in the ASIA scale showed
significant improvement in some patients, a finding
supported by neurophysiological studies.
In the present study, the patients showed improve-
ment in most sections of the IANR-SCIFRS scale, with
a clear parallelism between this improvement and that
obtained from the ASIA scale. In addition, improve-
ments in overall scores over ASIA, IANR-SCIFRS and
NBD scales showed a positive correlation with the
number of cells administered, suggesting that the ben-
eficial effect of our cell therapy is dose-dependent.The
high number of cells used in our trial may also explain
the important and early improvement obtained in the
manifestations of neurogenic bowel. Currently,
MSCs can be tracked in vivo after labeling with
superparamagnetic iron oxide nanoparticles [38], and
it is obvious that the use of these techniques can offer
in the future useful data to optimize doses and routes
of administration.
Although our analysis shows significant improve-
ments in FIM scale scores after treatment, in our
opinion, scales evaluating ADL are not very useful for
the assessment of chronic paraplegic patients because
they had generally adapted to chronic dysfunction and
were able to perform most activities of daily living
without assistance.
Neuropathic pain causes significant disability in
many paraplegic patients. In the present study, im-
provement in neuropathic pain was difficult to ascertain
because only seven patients had significant neuro-
pathic pain prior to treatment. However, we did observe
a tendency for the pain to decrease, with statistically
significant improvements in later stages of monitor-
ing, in both the VAS and the IANR-SCIFRS scale.
Early and progressive improvement in spasms and spas-
ticity was also a clear effect of the treatment.
To obtain objective evidence for improvements of
our patients, we performed neurophysiological and
urodynamic studies. In the neurophysiological studies,
all patients showed significant improvement during the
follow-up period after cell therapy, with the appear-
ance of previously abolished SSEPs or MEPs or with
EMG evidence of voluntary muscle contractions in
infralesional muscles. Given the progressive improve-
ment in neurophysiological studies, we think that long-
term monitoring of our patients is necessary.
The urodynamic findings support the improve-
ment in bladder function observed in the clinical scales.
In patients with complete and chronically established
paraplegia, reduced bladder capacity and increased de-
trusor muscle pressure are common findings.Therefore,
both increased bladder capacity (maximum cystometric
capacity) and decreased detrusor pressure are
urodynamic signs of clinical improvement. The ratio
of maximum cystometric capacity and detrusor pres-
sure determines bladder compliance, and, therefore,
an increase in bladder compliance objectively re-
flects the improvements in bladder function after
treatment.
In the present study, basal neuroimaging studies
enabled us to develop a personalized treatment. Al-
though the presence of surgical artefacts and the
difficulty in obtaining strictly superimposed images on
successive scans hindered the full assessment of pos-
sible changes after cell therapy, our treatment reduced
hyperintense SCI lesions observed in MR-myelography
images. In previous studies performed on our model
of chronic paraplegic minipigs [24], we described
similar neuroimaging findings when paraplegic minipigs
received intralesional cell therapy with administra-
tion parameters similar to those in the present study.
In these animals, histological studies showed that MRI
modifications were due to a progressive solidifica-
tion of intramedullary post-traumatic cavities, with
presence of regenerative phenomena [13].
Conclusions
In conclusion, our cell therapy treatment is a safe pro-
cedure. In the present clinical trial, we reproduced in
humans our previous experience with upper mammals,
and the results showed improvement in all patients,
in different aspects of the neurological disability as-
sociated with chronic complete paraplegia. The use
of a high number of cells, the characteristics of our
cell therapy medicament, which included a high con-
centration of cells in a small volume and the use of
autologous plasma as excipient, together with a per-
sonalized plan to select spinal cord targets where the
cells would be administered are crucial factors influ-
encing our results.
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